Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Genetic toxicity: in vitro

Currently viewing:

Administrative data

Endpoint:
in vitro cytogenicity / chromosome aberration study in mammalian cells
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2013-01-21 to 2013-02-25
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2013
Report date:
2013

Materials and methods

Test guidelineopen allclose all
Qualifier:
according to guideline
Guideline:
OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
Version / remarks:
The following alteration from the guidelines was performed:
The treatment of lymphocytes was started approx. 72 hours after mitogenic stimulation.
Deviations:
no
Qualifier:
according to guideline
Guideline:
EU Method B.10 (Mutagenicity - In Vitro Mammalian Chromosome Aberration Test)
Deviations:
no
Qualifier:
according to guideline
Guideline:
EPA OPPTS 870.5375 - In vitro Mammalian Chromosome Aberration Test
Deviations:
no
GLP compliance:
yes (incl. QA statement)
Type of assay:
in vitro mammalian chromosome aberration test

Test material

Constituent 1
Chemical structure
Reference substance name:
Methylphosphonic acid
EC Number:
213-607-2
EC Name:
Methylphosphonic acid
Cas Number:
993-13-5
Molecular formula:
CH5O3P
IUPAC Name:
methylphosphonic acid
Details on test material:
- Name of test material (as cited in study report): Methyl phosphonic acid 70%
- Molecular weight (if other than submission substance): 96.02 g/mol
- Analytical purity: 70 % in water
- Lot/batch No.: 0021634600
- Expiration date of the lot/batch: November 27, 2015
- Stability under test conditions: Stable in water
- Storage condition of test material: At room temperature
- CAS Number: 993-13-5

Method

Species / strain
Species / strain / cell type:
lymphocytes: human
Details on mammalian cell type (if applicable):
- Type and identity of media: Dulbeccos's modified Eagle's medium/Ham's F12 medium
- Properly maintained: yes
Metabolic activation:
with and without
Metabolic activation system:
rat liver S9
Test concentrations with justification for top dose:
With metabolic activation:
Experiment I: 8.9, 15.6, 27.3, 47.8, 83.6, 146.3, 256.0, 448.0, 784.0, 1372.0 µg/mL
Experiment II: 83.6, 146.3, 256.0, 448.0, 784.0, 1372.0 µg/mL

Without metabolic activation:
Experiment I: 8.9, 15.6, 27.3, 47.8, 83.6, 146.3, 256.0, 448.0, 784.0, 1372.0 µg/mL
Experiment II: 8.9, 15.6, 27.3, 47.8, 83.6, 146.3, 256.0, 448.0, 784.0, 1372.0 µg/mL
Vehicle / solvent:
- Vehicle(s)/solvent(s) used: Deionised water
- Justification for choice of solvent/vehicle: solubility and relatively low cytotoxicity in accordance to the OECD Guideline 473
Controlsopen allclose all
Untreated negative controls:
no
Negative solvent / vehicle controls:
yes
Positive controls:
yes
Positive control substance:
ethylmethanesulphonate
Untreated negative controls:
no
Negative solvent / vehicle controls:
yes
Positive controls:
yes
Positive control substance:
cyclophosphamide
Details on test system and experimental conditions:
Two independent experiments were performed. In Experiment I the exposure period was 4 hours with and without metabolic activation. In Experiment II the exposure period was 4 hours with S9 mix and 22 hours without S9 mix. The chromosomes were prepared 22 hours after start of treatment with the test item. Evaluation of two cultures per dose group.

METHOD OF APPLICATION: in culture medium

DURATION
- Exposure duration: 4 hours (+/- S9 mix) and 22 hours (- S9 mix)
- Fixation time (start of exposure up to fixation or harvest of cells): 22 hours

SPINDLE INHIBITOR (cytogenetic assays): Colcemid
STAIN (for cytogenetic assays): Giemsa

NUMBER OF REPLICATIONS: about 1.5

NUMBER OF CELLS EVALUATED: 100 per culture, except for the positive control in Experiment I in the presence of S9 mix, where only 50 metaphases were evaluated.

DETERMINATION OF CYTOTOXICITY
- Method: mitotic index

Evaluation criteria:
Evaluation of the cultures was performed (according to standard protocol of the "Arbeitsgruppe der Industrie, Cytogenetik") using NIKON microscopes with 100x oil immersion objectives. Breaks, fragments, deletions, exchanges, and chromosome disintegrations were recorded as structural chromosome aberrations. Gaps were recorded as well but not included in the calculation of the aberration rates. 100 well spread metaphases per culture were scored for cytogenetic damage on coded slides, except for the positive control in Experiment I in the presence of S9 mix, where only 50 metaphases were evaluated.
Only metaphases with characteristic chromosome numbers of 46 ± 1 were included in the analysis. To describe a cytotoxic effect the mitotic index (% cells in mitosis) was determined.
Statistics:
Statistical significance was confirmed by means of the Fisher´s exact test (p <0.05).

Results and discussion

Test results
Species / strain:
lymphocytes:
Metabolic activation:
with and without
Vehicle controls validity:
valid
Untreated negative controls validity:
not examined
Positive controls validity:
valid
Additional information on results:
The test item methylphosphonic acid , dissolved in deionised water, was assessed for its potential to induce chromosomal aberrations in human lymphocytes in vitro in the absence and presence of metabolic activation by S9 mix. Two independent experiments were performed. In Experiment I the exposure period was 4 hours with and without S9 mix. In Experiment II the exposure period was 4 hours with S9 mix and 22 hours without S9 mix. The chromosomes were prepared 22 hours after start of treatment with the test item. In each experimental group two parallel cultures were analysed. 100 metaphases per culture were scored for structural chromosomal aberrations, except for the positive control in Experiment I in the presence of S9 mix, where only 50 metaphases were evaluated. 1000 cells were counted per culture for determination of the mitotic index. The highest treatment concentration in this study, 1372.0 µg/mL (approx. 10 mM) was chosen with regard to the molecular weight and the purity (70 % in water) of the test item and with respect to the OECD Guideline for in vitro mammalian cytogenetic tests. No visible precipitation of the test item in the culture medium was observed. No relevant influence on osmolarity or pH value was observed. In this study, in the absence as well as in the presence of S9 mix, no biologically relevant cytotoxicity indicated by clearly reduced mitotic indices could be observed. In both experiments, in the absence and presence of S9 mix, no biologically relevant increase in the number of cells carrying structural chromosome aberrations was observed. The aberration rates of the cells after treatment with the test item (0.5 – 1.5 % aberrant cells, excluding gaps) were similar to the range of the solvent control values (0.5 – 1.5 % aberrant cells, excluding gaps) and within the range of the laboratory historical solvent control data. No evidence of an increase in polyploid metaphases was noticed after treatment with the test item as compared to the control cultures. In both experiments, either EMS (550.0 or 770.0 µg/mL) or CPA (15.0 or 20.0 µg/mL) were used as positive controls and showed distinct increases in cells with structural chromosome aberrations.
Remarks on result:
other: strain/cell type: human lymphocytes
Remarks:
Migrated from field 'Test system'.

Any other information on results incl. tables

Summary of results of the chromosomal aberration study with Methyl phosphonic acid 70%





































































































































































































































































Exp.



Preparation



Test item



Mitotic indices



Aberrant cells



 



 



interval



concentration



in %



in %



 



 



 



in µg/mL



of control



incl. gaps*



excl. gaps*



carrying exchanges



 



 



Exposure period 4 hrs without S9 mix



 



I



22 hrs



Solvent control1



100.0



1.0



0.5



0.0



 



 



 



Positive control2



51.6



24.5



24.0S



11.5



 



 



 



448.0



91.3



0.5



0.5



0.0



 



 



 



784.0



74.6



1.0



0.5



0.0



 



 



 



1372.0



95.6



2.0



1.5



0.0



 



 



Exposure period 22 hrs without S9 mix



 



II



22 hrs



Solvent control1



100.0



0.5



0.5



0.0



 



 



 



Positive control3



46.6



20.5



20.0S



4.5



 



 



 



448.0



82.5



1.0



1.0



0.0



 



 



 



784.0



107.7



1.5



1.5



0.0



 



 



 



1372.0



112.3



1.0



1.0



0.0



 



 



Exposure period 4 hrs with S9 mix



I



22 hrs



Solvent control1



100.0



1.5



1.5



0.0



 



 



 



Positive control4#



49.9



18.0



18.0S



1.0



 



 



 



448.0



93.4



1.0



1.0



0.0



 



 



 



784.0



96.7



0.5



0.5



0.0



 



 



 



1372.0



94.5



1.5



1.5



0.0



 



II



22 hrs



Solvent control1



100.0



1.5



1.0



0.0



 



 



 



Positive control5



49.6



14.5



13.5S



2.5



 



 



 



448.0



85.4



1.0



1.0



0.0



 



 



 



784.0



115.4



2.5



1.5



0.0



 



 



 



1372.0



90.0



1.5



1.5



0.0



 



 



 



 



 



 



 



 



 



 



 



 



 



 



*  Including cells carrying exchanges


#   Evaluation of 50 metaphases per culture due to strong clastogenic effects


S  Aberration frequency statistically significant higher than corresponding control values


1   Deionised water 10.0 % (v/v)


2     EMS     550.0 µg/mL


3        770.0 µg/mL


4     CPA       20.0 µg/mL


5   CPA       15.0 µg/mL


 

Applicant's summary and conclusion

Conclusions:
Methylphosphonic acid 70 % is considered to be non-clastogenic in this chromosome aberration test, when tested up to the highest required concentration.
Executive summary:

The test item methylphosphonic acid 70%, dissolved in deionised water, was assessed for its potential to induce structural chromosomal aberrations in human lymphocytes in vitro in two independent experiments. The following study design was followed:



































 



Without S9 mix



With S9 mix



 



Exp. I



Exp. II



Exp. I & II



Exposure period



 4 hrs



22 hrs



 4 hrs



Recovery



18 hrs



-



18 hrs



Preparation interval



22 hrs



22 hrs



22 hrs



In each experimental group two parallel cultures were analysed. Per culture 100 metaphases were evaluated for structural chromosomal aberrations, except for the positive control in Experiment I in the presence of S9 mix, where only 50 metaphases were evaluated. The highest applied concentration in this study (1372.0 µg/mL of the test item, approx. 10 mM) was chosen with regard to the molecular weight and the purity (70 % in water) of the test item and with respect to the current OECD Guideline 473. Dose selection of the cytogenetic experiment was performed considering the toxicity data in accordance with OECD Guideline 473. In the absence and presence of S9 mix, no cytotoxicity was observed up to the highest applied concentration. In both independent experiments, neither a statistically significant nor a biologically relevant increase in the number of cells carrying structural chromosomal aberrations was observed after treatment with the test item. No evidence of an increase in polyploid metaphases was noticed after treatment with the test item as compared to the control cultures. Appropriate mutagens were used as positive controls. They induced statistically significant increases in cells with structural chromosome aberrations.